Benzo [a]pyrene diol epoxide (BPDE, a carcinogen present in tobacco smoke and environmental pollution) has been shown to suppress retinoic acid receptor-beta2 (RAR-b 2 ) and induce cyclooxygenase-2 (COX-2) expression. Restoration of RAR-b 2 inhibited growth and colony formation of esophageal cancer cells, which was correlated with COX-2 suppression. In this study, we investigated the molecular mechanisms for RAR-b 2 -mediated suppression of COX-2 expression using BPDE as a tool. We found that BPDE-induced COX-2 expression was through inhibition of RAR-b 2 and consequently, induction of epidermal growth factor receptor (EGFR), extracellular signal-regulated protein kinases 1/2 (Erk1/2) phosphorylation, and c-Jun expression. Esophageal cancer cells that do not express RAR-b 2 did not respond to BPDE for induction of COX-2. BPDE was also unable to induce COX-2 expression after RAR-b 2 expression was manipulated in these esophageal cancer cells. Furthermore, BPDE induced time-dependent methylation of RAR-b 2 gene promoter in esophageal cancer cells. Transfection of RAR-b 2 expression vector into esophageal cancer cells suppressed expression of EGFR, Erk1/2 phosphorylation, c-Jun, and COX-2. In addition, co-treatment of RAR-b 2 -positive cells with BPDE and the MEK1/2 inhibitor U0126 caused little change in c-Jun and COX-2 expression. This study demonstrated that BPDE-suppressed expression of RAR-b 2 results in COX-2 induction and restoration of RAR-b 2 expression reduces COX-2 protein in esophageal cancer cells, thereby further supporting our previous finding that RAR-b 2 plays an important role in suppressing esophageal carcinogenesis.
Introduction
Esophageal cancer is one of the least studied and deadliest cancers in the world and is the seventh leading cause of cancer death among American men (DeVita et al., 1997; Richter, 1999; Posner, 2002) . In the United States, epidemiological studies have shown that the incidence of esophageal adenocarcinoma is increasing rapidly in the past decades, for reasons that not clear (McCann, 1999; Posner, 2002) . The body mass index (BMI) in the US may be linked to the increasing incidence rate of esophageal adenocarcinoma, as BMI is associated with gastroesophageal reflux and the development of Barrett's metaplasia that is a premalignant disorder (Mayne and Navarro, 2002; Posner, 2002; Enzinger and Mayer, 2003; Koch, 2003) . Furthermore, tobacco smoke is causally linked to both squamous cell carcinoma and adenocarcinoma of the esophagus (Enzinger and Mayer, 2003; US Surgeon Reports, 2004) . These two risk factors overlap and tobacco carcinogens may place obese-smokers into a very highrisk group for developing Barrette esophagus and adenocarcinoma. Tobacco smoke may enhance the effects of bile acid (a gastrointestinal tumor promoter and present in gastroesophageal reflux) in causing esophageal carcinogenesis.
Over the past three decades, a large body of knowledge has accumulated regarding the molecular alterations associated with esophageal carcinogenesis (DeVita et al., 1997; Richter, 1999; Posner, 2002; Enzinger and Mayer, 2003) . For example, COX-2 is frequently overexpressed in esophageal cancer cells and tissues and can be induced by various agents, such as growth factors, tumor promoters, and carcinogens (see review in Xu, 2002) . The contribution of cyclooxygenase-2 (COX-2) to carcinogenesis and the malignant phenotype of tumor cells is thought to be related to its abilities to (i) increase production of prostaglandins; (ii) convert procarcinogen to carcinogen; (iii) inhibit apoptosis; (iv) promote angiogenesis; (v) modulate inflammation and immune function; and (vi) increase tumor cell invasiveness.
Our studies have shown that retinoic acid receptorbeta2 (RAR-b 2 ) expression is progressively lost in dysplastic lesions of esophageal mucosa and in both esophageal SCC and adenocarcinoma (Xu et al., 1999b; Qiu et al., 1999; Zhang et al., 2001) , which was further confirmed by other groups (Xu et al., 2002a; Kuroki et al., 2003; Su et al., 2003; Wang et al., 2003; Liu et al., 2004) . We also found that transfection of RAR-b 2 decreased growth and colony formation and induced apoptosis in esophageal cancer cells, which was correlated with the reduced expression of COX-2 (Li et al., 2002) . Our further study revealed that Benzo[a]pyrene diol epoxide (BPDE) (a carcinogen present in tobacco smoke and environmental pollution) suppressed RARb 2 expression and induced COX-2 expression (Song and Xu, 2001) . Other studies have shown that lung cancer cells expressing transfected RAR-b 2 exhibited lower tumorigenicity than nontransfected cells in nude mice (Houle et al., 1993) , and lung cancer developed in transgenic mice expressing antisense RAR-b 2 (Berard et al., 1996) . Knockout of the RAR-b 2 gene by homologous recombination in F9 cells eliminated retinoid-associated growth arrest, altered cell morphology, and partially affected the differentiation potential (Faria et al., 1999) . RAR-b 2 expression is frequently and progressively lost in premalignant and malignant tissues of different human cancers (see review in Xu and Lotan, 1999) . Induction of RAR-b 2 in vivo has been used as a biomarker in several clinical chemoprevention trials by researchers at our institution and by other groups (Lotan et al., 1995 Ayoub et al., 1999; Berg et al., 1999; Xu et al., 1999a; Kurie et al., 2000 Kurie et al., , 2003 Lam et al., 2003; Alberts et al., 2004) . Taken together, all these data support that RAR-b 2 plays important roles in suppressing human cancer development. However, the molecular mechanisms for RAR-b 2 -mediated effects on tumors are less well understood although previous studies have identified some interesting RAR-b 2 -targeting genes using RAR-b 2 -transfected or knockout cells (Toulouse et al., 2000; Xu et al., 2002b; Zhuang et al., 2003, pp. 122-124) . In this study, we investigated the molecular mechanisms by which RAR-b 2 controls COX-2 expression using BPDE as a tool.
Results

BPDE-induced expression of COX-2 correlated with suppression of RAR-b 2
Our previous studies (Li et al., 2002; Song and Xu, 2001) have shown that BPDE inhibited RAR-b 2 and induced COX-2 expression, whereas restoration of RAR-b 2 was able to suppress expression of COX-2 mRNA and protein. We therefore attempted to determine whether these two events are inter-related. Our data showed that BPDE-induced COX-2 expression was correlated with its suppression of RAR-b 2 and increase in EGFR expression, that is, SV-40-immortalized esophageal epithelial cell line HET-1A and esophageal SCC cell lines TE-3 and TE-12 expressed RAR-b 2 and treatment of these cells with 1 mM BPDE for 12 h suppressed RAR-b 2 and induced EGFR and COX-2 expression. However, BPDE treatment was unable to induce COX-2 expression in RAR-b 2 -negative cell lines TE-1 and TE-8 (Figure 1a and c) . Furthermore, we also determined whether BPDE could induce COX-2 expression in those cell lines whose RAR-b 2 expression was altered by transfection, that is, TE8-S20 and TE8-S22 cells are the stable RAR-b 2 sense-transfected TE-8 sublines, TE3-A3 and TE3-A5 cells are the stable RAR-b 2 antisensetransfected TE-3 sublines, and TE-3/RAR-b 2 cells are the transient RAR-b 2 sense-transfected TE-3 cells. After these cell lines were treated with 1 mM BPDE for 12 h, Western blotting did not show any changes of COX-2 expression (Figure 1b and c) although the vector-control TE-3V1 cells showed induction of COX-2 expression by BPDE (Figure 1b) . To determine the molecular signaling pathway in BPDE-induced COX-2 expression, we analysed those genes that might be responsible for the upregulation of COX-2. We first determined the protein levels of total and phosphorylated extracellular signal-regulated protein kinases 1/2 (Erk1/2), c-Jun, and total and phosphorylated Jun N-terminal kinase (JNK) and p38 MAPK after treating esophageal cell lines TE-3, TE-8, and TE-12 with 1 mM BPDE for up to 24 h. As shown in Figure 3 , RAR-b 2 expression was suppressed in TE-3 and TE-12 cells after treatment with 1 mM BPDE, which was correlated with the induction of Erk1/2 phosphorylation and c-Jun and COX-2 protein levels but not with the phosphorylation of JNK and p38 (total JNK and p38 data not shown). In contrast, TE-8 cells, which do not express RAR-b 2 (Figure 1 ), showed little change in expression of any of these proteins although some reduction of phosphorylated p38 was shown.
To further determine whether modulation of RAR-b 2 expression in these esophageal cancer cell lines will alter expression of the above-named genes, we performed Western blotting assay to analyse the expression of these genes in stable RAR-b 2 sense-transfected TE-8 cells and stable RAR-b 2 antisense-transfected TE-3 cells. As shown in Figure 4 , the induction of RAR-b 2 in esophageal cancer cell lines TE-8S20 and TE8-S22 downregulated expression of EGFR, phosphorylated Erk1/2, c-Jun, and COX-2 proteins, whereas blocking RAR-b 2 expression in TE-3A3 and TE3-A5 cells induced expression of EGFR, phosphorylated Erk1/2, c-Jun, and COX-2 proteins. Furthermore, transient transfection of the AP-1 or COX-2 promoter with the luciferase reporter gene also showed that RAR-b 2 plays a role in inhibiting the activities of the AP-1 or COX-2 promoters in these cells ( Figure 5 ).
In addition, we injected subcutaneously the stable RAR-b 2 antisense-transfected cells TE3-A5 and the vector-only-transfected cells TE-3-V1 (1 Â 10 6 per mouse in six mice) into the right flank of nu/nu nude mice and then monitored for tumor formation for more than Erk1/2 phosphorylation inhibitor, U0126, blockage of BPDE-induced Erk1/2 phosphorylation, and c-Jun and COX-2 expression We used MEK1/2 inhibitor U0126, which can block Erk1/2 phosphorylation, to determine whether blocking Erk1/2 phosphorylation would antagonize the effect of BPDE on induction of c-Jun and COX-2 expression. As shown in Figure 7 , the effect of BPDE on Erk1/2 phosphorylation was largely blocked in TE-3 and TE-12 cells after the cells were treated with 1 mM U0126; in turn, expression of c-Jun and COX-2 was not changed in these cells. However, neither BPDE nor U0126 changed the total amount of Erk1/2 (data not shown). Furthermore, cotreatment with U0126 and BPDE blocked AP-1 promoter luciferase activity after stimulation with BPDE ( Figure 7b ).
Participation of AP-1 gene family members in BPDE-induced COX-2 expression
AP-1 gene family includes different genes that have different roles in regulating cell growth, transformation, and apoptosis (Mechta-Grigoriou et al., 2001) . It is therefore important to identify which AP-1 proteins mediate the effect of BPDE on COX-2 induction. Thus, we performed gel shift assay to determine which AP-1 proteins participate in the AP-1 complex. We found that the density of the AP-1 complex was increased significantly in TE-3 and TE-12 cells after these cells were treated with BPDE. The specificity of the binding was confirmed by using mutant AP-1 oligonucleotides. Supershift assay in which antibodies were used against various AP-1 family members showed that JunB was the most abundant component in the AP-1 binding complex, followed by Fra-1, c-Fos, c-Jun, and FosB (Figure 8 ). There was no evidence of JunD and Fra-2 participating in this complex.
Discussion
Our current study has demonstrated that the induction of COX-2 expression by BPDE is dependent first on expression and then on inhibition of RAR-b 2 and consequently, increases in EGFR protein, Erk1/2 phosphorylation, and c-Jun expression in RAR-b 2 -positive esophageal cells. In contrast, esophageal cancer cells that do not express RAR-b 2 or have RAR-b 2 expression altered did not respond to BPDE for induction of COX-2 expression. These findings indicate that RAR-b 2 controls COX-2 expression through suppression of Erk1/2/AP-1 pathway genes and suggest that BPDE has an indirect effect on COX-2 expression. Furthermore, our data have demonstrated that BPDE treatment caused time-dependent methylation of RARb 2 gene promoter in esophageal cancer cells.
RAR-b 2 expression is frequently and progressively lost in premalignant and malignant tissues of various human cancers, including esophageal cancer (see review in Xu and Lotan, 1999) . A study using animal model has demonstrated that cigarette smoke downregulated RAR-b 2 expression but not RAR-a or RAR-g in ferrets compared to the control animals and meanwhile, AP-1 expression was significantly upregulated in the ferrets exposed to cigarette smoke compared to the controls (Wang et al., 1999) . A study by another group also showed that nuclear retinoid receptors were potent inhibitors of AP-1 activity generated by either c-Jun homodimers or c-Jun/c-Fos heterodimers (Yang-Yen et al., 1991) . RAR-b 2 can inhibit AP-1 activity (Lin et al., 2000b) , and the COX-2 promoter contains an AP-1 consensus sequence that is known to activate COX-2 promoter activity (Mechta-Grigoriou et al., 2001) . Taken together, all these data support that RAR-b 2 functions as a tumor suppressor gene.
Our current study showed that several members of the AP-1 gene family mediate the effects of BPDE on COX-2 expression. JunB was the most abundant component in Figure 4) were grown in monolayer for 24 h and then transiently transfected with AP-1 or COX-2 promoter-luciferase reporter plasmids for an additional 24 h. Cellular protein was then extracted, and its luciferase activity was measured. The experiments were performed in triplicate and repeated twice; the results reported here are the mean7s.d. of all these experiments the AP-1 binding complex, followed by Fra-1, c-Fos, cJun, and FosB. However, JunD and Fra-2 showed no supershift bands from the AP-1 nuclear complex. Previous studies have shown that c-Jun, a positive regulator in cell proliferation, can increase cyclin D1 and decrease p16 and p19 expression, leading to cell proliferation and transformation (Shaulian and Karin, 2001); conversely, overexpression of JunD in immortalized fibroblasts slows their proliferation and induces their accumulation at the G1 phase of the cell cycle (Pfarr et al., 1994) . Therefore, further studies are needed to define the molecular signaling of the AP-1 gene family members that affects BPDE-induced COX-2 expression.
Previous studies have shown the particular importance of retinoic acid in the suppression of EGFR expression (Grandis et al., 1996; Dragnev et al., 2003; Lango et al., 2003) . Retinoic acid suppressed EGFassociated cell proliferation through inhibition of EGFR-dependent Erk1/2 activation (Sah et al., 2002) . Immortalized human bronchial epithelial cells can be malignantly transformed by the tobacco carcinogen NNK, which is associated with overexpression of EGFR and cyclin D1, while retinoic acid treatment can prevent this transformation by downregulation of EGFR and cyclin D1 (Dragnev et al., 2003) . These studies indicate that retinoic acid can induce RAR-b 2 expression and then suppress the expression of EGFR and phosphorylated Erk1/2. Furthermore, RAR-b 2 sense-or antisensetransfected esophageal cancer cells showed suppressed or induced COX-2 expression, respectively, which was correlated with the sensitivity of the cells to retinoic acid in cell growth and colony formation (Li et al., 2002 ). In the current study, we have shown that BPDE lost its ability to induce COX-2 expression in these cells, suggesting that the effect of BPDE on COX-2 expression is mediated through inhibition of RAR-b 2 expression. It is because induction or suppression of RAR-b 2 expression in RAR-b 2 sense-or antisense-transfected esophageal cancer cells was controlled by a plasmid that contains a CMV promoter and thus, BPDE was unable to regulate RAR-b 2 expression in these cells any more. Therefore, BPDE cannot induce COX-2 expression in these cells. (c) Detection of EGFR, phosphorylated Erk1/2, and COX-2 expression in mouse tumor xenografts by using immunohistochemistry or in situ hybridization. Consecutive paraffin sections from mouse xenografts were immunostained with anti-EGFR and phosphorylated Erk1/2 antibodies, or hybridized with digoxigenin-labeled cRNA probe for COX-2
In a study of the molecular mechanisms for the lost expression of RAR-b 2 in human cancers, multiple mechanisms have been discovered (see review in Xu and Lotan, 1999) . For example, in some of the nonsmall-cell lung cancers, chromosome 3p deletion may be the cause (Gebert et al., 1991) , but not in esophageal cancer (Qiu et al., 2000) . Another possible mechanism that has been explored is the role of various other transcription factors in the regulation of RAR-b 2 expression. Two orphan receptors, nurr77 and COUP-TF, have been reported to be important in the regulation of RAR-b 2 expression in tumor cells (Wu et al., 1997; Lin et al., 2000a) . However, a great number of studies using tissue specimens from different cancer patients demonstrated that RAR-b 2 gene promoter is frequently methylated and the treatment with 5-aza-2 0 -deoxycytidine, a DNA demethylation agent, can restore RAR-b 2 expression in various cancer cell lines (Cote et al., 1998; Virmani et al., 2000; Widschwendter et al., 2000; McGregor et al., 2002; Wang et al., 2003; Kim et al., 2005) . Our current data found that BPDE was able to cause methylation of RAR-b 2 promoter, which was correlated with suppression of RAR-b 2 expression and induction of COX-2 expression, both of which are frequently altered in different cancers, including esophageal cancer (see review in Xu and Lotan, 1999; Xu, 2002) . Therefore, our current study mechanistically linked esophageal cancer risk factors to its molecular alterations, which may help us in future to develop novel strategies to conquer this now deadly disease using chemopreventive agents to antagonize the effects of BPDE on esophageal epithelial cells. Further studies will investigate the molecular mechanisms for BPDE-induced methylation of RAR-b 2 gene promoter. 
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Materials and methods
Cell culture and treatment
Esophageal squamous cancer cell lines TE-1, TE-3, TE-8, and TE-12, as well as the stable RAR-b 2 -transfected TE-8S20 and TE-8S22 cell lines and stable RAR-b 2 antisense-transfected TE-3A3 and TE-3A5 cell lines (see details in Li et al., 2002) , were plated in tissue culture dishes and grown in Dulbecco's modified Eagle's medium (DMEM) plus 10% fetal bovine serum (FBS) at 371C in a humidified atmosphere of 95% air and 5% CO 2 . The growth medium for the stable cell lines also included 200 mg/ml G418. The SV-40-immortalized esophageal epithelium cell line HET-1A (Song and Xu, 2001 ) was grown in LHC-8 medium in tissue culture dishes that were precoated with a mixture of 18 mg of fibronectin, 18 ml of vitrogen, 180 ml of 10 Â bovine serum albumin, and 2 ml of LHC-basal medium (Biofluids Co., Rockville, MD, USA) at 371C in a humidified atmosphere of 96.5% air and 3.5% CO 2 . To determine the effects of BPDE and U0126 (a specific MEK1/2 inhibitor), the cells were plated in DMEM for 24 h, the medium was then replaced with control medium (containing 0.01% dimethylsulfoxide or tetrahydrofuran), BPDE (Midwest Research Institute, Kansas City, MO, USA), or U0126 (Calbiochem, San Diego, CA, USA). BPDE was dissolved in tetrahydrofuran (Sigma Chemical Co., St Louis, MO, USA), and U0126 was dissolved in DMSO. Both solutions were then diluted with growth medium before each experiment.
RNA purification and Northern blotting analysis
Tri-Reagent (Molecular Research Center, Cincinnati, OH, USA) was used to extract RNA from monolayer cultures, and the plasmid pRC/CMV (Invitrogen, San Diego, CA, USA), which contains human RAR-b 2 cDNA, was used as the Northern blotting probe, as described previously (Xu et al., 1999b; Li et al., 2002) .
Protein extraction and Western blotting
Cellular and nuclear proteins were isolated as described by Xu et al. (1999b) and Li et al. (2002) . The protein concentration was then measured with a BioRad Protein Assay Kit II (BioRad Laboratories, Hercules, CA, USA) according to the manufacturer's protocol. Samples containing 50 mg of protein from control or treated cells were separated by 10% polyacylamide SDS-PAGE gels and then transferred electrophoretically to a Hybond-C nitrocellulose membrane (Amersham-Pharmacia, Arlington Heights, IL, USA) at 500 mA for 2 h at 41C. The membrane was subsequently stained with 0.5% ponceau S containing 1% acetic acid to confirm that proteins were loaded equally and to verify transfer efficiency. The membranes were next incubated overnight in a blocking solution containing 5% bovine skim milk and 0.1% Tween 20 in PBS at 41C. The next day, the membranes were incubated with primary antibodies for 2 h at room temperature. The antibodies used were anti-c-Jun/AP-1, c-Fos, and phosphorylated-JNK (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA); anti-COX-2 (DB Transduction Laboratories, Lexington, KY, USA); anti-Erk1/2, phosphoErk1/2, and phospho-p38 (Cell Signaling Technology, Beverly, MA, USA); and anti-b-actin antibody (Sigma). The membranes were washed in PBS and incubated for 1.5 h with horse anti-mouse or goat anti-rabbit secondary antibody (Amersham-Pharmacia) diluted 1 : 5000. After this, the membranes were incubated with enhanced chemiluminescence solution (Amersham-Pharmacia) for 1-2 min and exposed to an X-ray film.
Transient transfection and luciferase assay
The cells were seeded at a concentration of 1.5 Â 10 5 cells per well in six-well plates. After an overnight culture, the cells in each well were transfected with DNA (1 mg of AP-1-or COX-2-luciferase reporter plasmids and 0.1 mg of pCH110) using 3 ml of Fugene6 (Roche, Indianapolis, IN, USA) following the manufacturer's protocol. The AP-1 promoterluciferase reporter plasmid was kindly provided by Dr Jonathan Kurie from our institution. The COX-2 promoterluciferase reporter plasmid was used in our previous publication (Song and Xu, 2001 ). pCH110, a b-galactosidase expression vector (Amersham-Pharmacia), was used as an internal control for assessing transfection efficiency. After 24 h of exposure to the transfection mixture, the cells were incubated in medium containing 10% FBS plus 0.1 or 1 mM U0126 for 2 h and then 1 mM BPDE was added for another 12 h. The cells were then harvested so that b-galactosidase and luciferase activities could be measured. These activities were measured using the Promega (Madison, WI, USA) luciferase assay system according to the manufacturer's protocol (Technical Manual TM033). Turner Designs Luminometer Model TD-20/20 (Promega) recorded the luciferase activity in relative light units that were normalized to the bgalactosidase activity to correct for differences in transfection efficiency. All experiments were performed in triplicate and repeated at least twice to confirm the reproducibility of the results.
Methylation-specific PCR
Esophageal cancer cell lines TE-3 and TE-12 that express RAR-b 2 were treated with 1 mM BPDE for up to 24 h and genomic DNA was extracted and subjected to methylationspecific PCR analysis as described previously . Primers used to amplify the methylated RAR-b 2 gene were 5 0 -TCGAGAACGCGAGCGATTCG-3 0 (sense) and 5 0 -GACCAATCCAACCGAAACGA-3 0 (antisense). Primers used to amplify the unmethylated RAR-b 2 gene were 5 0 -TTGAGAATGTGAGTGATTTGA-3 0 (sense) and 5 0 -AAC CAATCCAACCAAAACAA-3 0 (antisense).
Animal experiments
An Institutional Animal Care and Usage protocol was approved by our institutional IACUC. Briefly, three nu/nu nude mice (6-8 weeks of age) were implanted subcutaneously in the right flank with 1 Â 10 6 cells per mouse and injection with a 22-gauge needle. The animals were then monitored for tumor formation until most tumor burdens from the vectoronly-transfected cells disappeared. The xenografts were then taken out and analysed for expression of EGFR, phosphorylated Erk1/2, and COX-2 by immunohistochemistry or in situ hybridization (see below). The experiments were repeated once with additional three mice.
Immunohistochemistry
Immunohistochemical studies were performed using an avidin-biotin complex technique as described previously (Zhang et al., 2001 ) with a monoclonal anti-EGFR and phosphorylated Erk1/2 antibodies (Cell Signaling Inc., Beverly, MA, USA) at a dilution of 1 : 50. The stained sections were reviewed and scored using an Olympus microscope. The sections were then scored as having 0, þ , þ þ , or þ þ þ staining according to their staining intensity.
In situ hybridization A previously described method of nonradioactive in situ hybridization was used for detection of COX-2 expression (Khuri et al., 2001; Kong et al., 2005) . The stained sections were reviewed in a manner similar to immunohistochemistry.
Gel shift assay
TE-3 and TE-12 cells were treated with 1 mM BPDE for 12 h, and then nuclear extracts from these cells were prepared as described elsewhere (Song and Xu, 2001 ). The DNA-binding reaction was carried out at room temperature for 20 min in a mixture containing 5 mg of nuclear proteins, 2 mg of poly (deoxyinosinic acid deoxycytidylic acid), and 100 000 c.p.m. of either a 32 P-labeled double-stranded AP-1 consensus oligonucleotide (5 0 -CGCTTGATGAGTCAGCCGGAA-3 0 ) or AP-1 mutant oligonucleotide with a CA-to-TG substitution in the AP-1 binding motif (both from Santa Cruz Biotechnology Inc.). The samples were then fractionated through a 5% polyacrylamide gel in 0.5 Â TBE (1 Â TBE contains 90 mM Tris base, 64.6 mM boric acid, and 2 mM EDTA (pH 8.0)). The gel was then dried and subjected to autoradiography at À801C. A supershift assay of the AP-1 complex was performed by preincubating 5 mg of nuclear protein with 1 mg of antibody against c-Jun, JunB, JunD, c-Fos, FosB, Fra-1, or Fra-2 (all from Santa Cruz Biotechnology Inc.) at 41C for 30 min and then processed as described above.
